Cepheid is a molecular diagnostics company. The Company develops, manufactures and markets fully-integrated systems for testing in the Clinical and Non-Clinical markets. The Company's systems enable molecular testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures. The Company's systems integrate these steps and analyze biological samples in test cartridges. Its primary offering is the GeneXpert system, which integrates sample preparation in addition to Deoxyribonucleic acid (DNA) amplification and detection. The GeneXpert system is designed for a range of user types ranging from reference laboratories and hospital central laboratories to satellite testing locations, such as emergency departments and intensive care units within hospitals, as well as physician offices and other alternate site laboratories. It also offers the SmartCycler system, which integrates DNA amplification and detection to allow rapid analysis of a sample.
Industry, Sector and Symbol
Industry N/A
Sub-IndustryBiotechnology
SectorN/A
Phone+1-408-5414191
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable
Cepheid (NASDAQ:CPHD) Frequently Asked Questions
What is Cepheid's stock symbol?
Cepheid trades on the NASDAQ under the ticker symbol "CPHD."
How were Cepheid's earnings last quarter?
Cepheid (NASDAQ:CPHD) announced its quarterly earnings results on Thursday, July, 28th. The scientific and technical instruments company reported $0.05 earnings per share for the quarter, beating analysts' consensus estimates of ($0.14) by $0.19. The scientific and technical instruments company earned $146 million during the quarter, compared to the consensus estimate of $145.82 million. The business's revenue was up 10.2% on a year-over-year basis. During the same quarter last year, the company earned ($0.06) earnings per share. View Cepheid's Earnings History.
Has Cepheid been receiving favorable news coverage?
News articles about CPHD stock have been trending somewhat positive this week, according to InfoTrie Sentiment Analysis. InfoTrie rates the sentiment of news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Cepheid earned a daily sentiment score of 1.0 on InfoTrie's scale. They also assigned news articles about the scientific and technical instruments company a news buzz of 5.0 out of 10, indicating that recent news coverage is somewhat likely to have an effect on the company's share price in the immediate future.
What other stocks do shareholders of Cepheid own?
How do I buy shares of Cepheid?
Shares of CPHD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cepheid's official website?
How can I contact Cepheid?
Cepheid's mailing address is 904 E Caribbean Dr, SUNNYVALE, CA 94089-1189, United States. The scientific and technical instruments company can be reached via phone at +1-408-5414191.
MarketBeat Community Rating for Cepheid (NASDAQ CPHD)
MarketBeat's community ratings are surveys of what our community members think about Cepheid and other stocks. Vote "Outperform" if you believe CPHD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CPHD will underperform the S&P 500 over the long term. You may vote once every thirty days.
